We've found
52,953 Cancer
clinical trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 11/30/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Cancer Clinical Trial
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Cancer Clinical Trial
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology, Oncology Clinical Trial
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Status: Enrolling,
Phase
II
Updated: 6/1/2016
Click here to add this to my saved trials
Oncology Clinical Trial
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Status: Enrolling,
Phase
II
Updated: 6/1/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
We've found
52,953 Cancer
clinical trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Endocrinology, Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology, Reproductive Clinical Trial
Updated: 12/31/1969
Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 4/7/2016
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
Status: Enrolling,
Phase
III
Updated: 4/7/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 5/17/2016
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 5/17/2016
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 5/17/2016
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Status: Enrolling,
Phase
III
Updated: 5/17/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Updated: 12/31/1969
Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Updated: 12/31/1969
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Updated: 12/31/1969
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Updated: 12/31/1969
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Advanced Solid Tumors Clinical Trial
Updated: 12/31/1969
Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology, Other Clinical Trial
Updated: 12/31/1969
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
Updated: 11/30/2016
Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 11/30/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
Updated: 12/31/1969
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
Updated: 12/31/1969
MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Solid Tumors Clinical Trial
Updated: 12/31/1969
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Hematology, Oncology Clinical Trial
Updated: 12/31/1969
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Updated: 12/31/1969
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Non-Small Cell Lung Cancer Clinical Trial
Updated: 12/31/1969
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Status: Enrolling,
Phase
II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Updated: 12/31/1969
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Updated: 12/31/1969
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Updated: 12/31/1969
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Updated: 12/31/1969
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Musculoskeletal, Oncology, Pulmonary / Respiratory Diseases, Other Clinical Trial
Updated: 12/31/1969
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
Status: Enrolling,
Phase
II, III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
Status: Enrolling,
Phase
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 4/30/2018
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 4/30/2018
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 4/30/2018
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Status: Enrolling,
Phase
II
Updated: 4/30/2018
Click here to add this to my saved trials
Cancer Clinical Trial
Updated: 12/31/1969
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Cancer Clinical Trial
Updated: 12/31/1969
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Status: Enrolling,
Phase
I
Updated: 12/31/1969
Click here to add this to my saved trials
Gastroenterology, Oncology Clinical Trial
Updated: 12/31/1969
S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction
Status: Enrolling,
Phase
III
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 12/31/1969
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Status: Enrolling,
Phase
I, II
Updated: 12/31/1969
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 6/1/2016
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Status: Enrolling,
Phase
II
Updated: 6/1/2016
Click here to add this to my saved trials
Oncology Clinical Trial
Updated: 6/1/2016
A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)
Status: Enrolling,
Phase
II
Updated: 6/1/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials
Urothelial Cancer Clinical Trial
Updated: 5/17/2016
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)
Status: Enrolling,
Phase
II
Updated: 5/17/2016
Click here to add this to my saved trials